MBX Biosciences, Inc. Diluted Shares Outstanding (Weighted Average)
MBX Biosciences, Inc. (MBX) reported Diluted Shares Outstanding (Weighted Average) of 47.70 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- MBX Biosciences, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 47.70M shares, a 42.61% increase year-over-year.
- MBX Biosciences, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 46.58M shares, a 39.40% increase year-over-year.
- MBX Biosciences, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 44.96M shares, a 33.97% increase year-over-year.
- MBX Biosciences, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 34.20M shares, a 424.87% increase year-over-year.
- MBX Biosciences, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 36.51M shares, a 243.01% increase from fiscal 2024.
- MBX Biosciences, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 10.64M shares, a 944.70% increase from fiscal 2023.
- MBX Biosciences, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 1.02M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 47.70M shares 10-Q · filed 2026-08-06 | 47.14M shares 10-Q · filed 2026-08-06 | 46.41M shares derived: average of 3 quarters · filed 2026-08-06 | 43.36M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 46.58M shares 10-Q · filed 2026-05-07 | 45.77M shares derived: average of 2 quarters · filed 2026-05-07 | 41.91M shares derived: average of 3 quarters · filed 2026-05-07 | 39.79M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 44.96M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 39.58M shares derived: average of 2 quarters · filed 2026-03-12 | 37.53M shares derived: average of 3 quarters · filed 2026-08-06 | 36.51M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 34.20M shares 10-Q · filed 2025-11-06 | 33.82M shares derived: average of 2 quarters · filed 2026-08-06 | 33.69M shares 10-Q · filed 2025-11-06 | 33.65M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 33.45M shares 10-Q · filed 2026-08-06 | 33.43M shares 10-Q · filed 2026-08-06 | 33.47M shares derived: average of 3 quarters · filed 2026-08-06 | 26.73M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 33.41M shares 10-Q · filed 2026-05-07 | 33.49M shares derived: average of 2 quarters · filed 2026-05-07 | 24.50M shares derived: average of 3 quarters · filed 2026-05-07 | 18.69M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 33.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 20.04M shares derived: average of 2 quarters · filed 2026-03-12 | 13.78M shares derived: average of 3 quarters · filed 2026-03-12 | 10.64M shares 10-K · filed 2026-03-12 |
| 2024-09-30 | 6.52M shares 10-Q · filed 2025-11-06 | 3.89M shares derived: average of 2 quarters · filed 2025-11-06 | 3.00M shares 10-Q · filed 2025-11-06 | 2.53M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 1.26M shares 10-Q · filed 2025-08-07 | 1.23M shares 10-Q · filed 2025-08-07 | 1.20M shares derived: average of 3 quarters · filed 2025-08-07 | 1.17M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 1.20M shares 10-Q · filed 2025-05-12 | 1.17M shares derived: average of 2 quarters · filed 2025-05-12 | 1.14M shares derived: average of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | 1.14M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 1.11M shares derived: average of 2 quarters · filed 2025-03-17 | 1.02M shares 10-K · filed 2025-03-17 | |
| 2023-09-30 | 1.08M shares 10-Q · filed 2024-11-07 | 976.82K shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |